As the U.S. markets face turbulence with stocks sliding ahead of potential new tariffs, investors are keeping a close watch on economic indicators amid recession fears. In such uncertain times, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities for those looking to diversify their portfolios. While traditionally seen as speculative, these stocks can still provide growth potential when backed by solid financial health and strategic positioning in the market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.74 | $391.07M | ✅ 3 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $3.33 | $2.03B | ✅ 3 ⚠️ 3 View Analysis > |
| Cango (NYSE:CANG) | $3.94 | $438.33M | ✅ 4 ⚠️ 1 View Analysis > |
| Sensus Healthcare (NasdaqCM:SRTS) | $4.64 | $80.5M | ✅ 5 ⚠️ 3 View Analysis > |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ✅ 1 ⚠️ 5 View Analysis > |
| TETRA Technologies (NYSE:TTI) | $3.53 | $471.32M | ✅ 5 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.52 | $77.95M | ✅ 3 ⚠️ 1 View Analysis > |
| BAB (OTCPK:BABB) | $0.791 | $6.17M | ✅ 2 ⚠️ 3 View Analysis > |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $138.01M | ✅ 3 ⚠️ 1 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.85 | $78.28M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 767 stocks from our US Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
SurgePays (NasdaqCM:SURG)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: SurgePays, Inc. operates as a financial technology and telecom company in the United States with a market cap of $46.72 million.
Operations: SurgePays, Inc. has not reported any specific revenue segments.
Market Cap: $46.72M
SurgePays, Inc., with a market cap of US$46.72 million, has experienced significant volatility in its share price over the past three months. Despite this, the company has not diluted shareholders meaningfully in the past year and boasts an experienced board and management team. SurgePays reported a net loss of US$45.73 million for 2024 but anticipates revenue exceeding US$200 million in 2025 due to strategic initiatives like LinkUp Mobile's national launch and expanding MVNE partnerships. The recent partnership with GPO Plus aims to enhance sales outreach through SurgePays' robust retail network, potentially boosting operational efficiency and market presence for both companies.
- Click here to discover the nuances of SurgePays with our detailed analytical financial health report.
- Assess SurgePays' future earnings estimates with our detailed growth reports.
Exagen (NasdaqGM:XGN)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Exagen Inc. develops and commercializes testing products under the AVISE brand in the United States, with a market cap of approximately $69.09 million.
Operations: Exagen's revenue is primarily derived from its diagnostic kits and equipment, totaling $55.64 million.
Market Cap: $69.09M
Exagen Inc., with a market cap of US$69.09 million, has shown resilience amid volatility, as its short-term assets exceed both short and long-term liabilities. Despite being unprofitable with a negative return on equity, Exagen's revenue grew to US$55.64 million in 2024 from US$52.55 million the previous year, and it forecasts further growth in 2025. The company recently received conditional approval for new biomarker assays for lupus and rheumatoid arthritis, potentially enhancing its AVISE platform's diagnostic utility. Although debt levels have risen significantly over five years, Exagen holds more cash than total debt, providing some financial stability.
- Jump into the full analysis health report here for a deeper understanding of Exagen.
- Gain insights into Exagen's future direction by reviewing our growth report.
Healthier Choices Management (OTCPK:HCMC)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Healthier Choices Management Corp. operates natural and organic retail stores in the United States with a market cap of $481,266.
Operations: The company generates revenue from its vapor segment, which amounts to $0.000923 million.
Market Cap: $481.27k
Healthier Choices Management Corp., with a market cap of US$481,266, operates in the natural and organic retail space but is pre-revenue given its minimal income from the vapor segment. The company recently changed auditors following a subsidiary spin-off, indicating strategic shifts. Despite high volatility and unprofitability with losses escalating over five years by 45.6% annually, HCMC maintains more cash than debt and covers short-term liabilities with assets totaling US$3.4 million. However, its cash runway is limited if free cash flow continues to decline at historical rates, posing potential challenges for sustained operations without further financing or revenue growth initiatives.
- Click here and access our complete financial health analysis report to understand the dynamics of Healthier Choices Management.
- Assess Healthier Choices Management's previous results with our detailed historical performance reports.
Taking Advantage
- Click through to start exploring the rest of the 764 US Penny Stocks now.
- Contemplating Other Strategies? Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Exagen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com